Skip to content

Evaluation of the Results of Simultaneous Pancreatic and Hepatic Resections for Metastatic Neuroendocrine Tumors.

Evaluation of the Results of Simultaneous Pancreatic and Hepatic Resections for Metastatic Neuroendocrine Tumors

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05528614
Acronym
ReSiPaTNE
Enrollment
51
Registered
2022-09-06
Start date
2022-01-13
Completion date
2023-01-13
Last updated
2023-11-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Tumor of Pancreas

Keywords

Tumor of Pancreas, Metastatic neuroendocrine tumors, Hepatic resection, Pancreatic resection

Brief summary

The indications for synchronous liver resection for metastatic neuroendocrine tumors of pancreatic origin remain debated and poorly described in the literature. The reported mortality of this type of simultaneous resection remains very high, especially when a cephalic duodenopancreatectomy is associated with a hepatic resection (up to 40%). The benefit in terms of survival remains to be evaluated. The ReSiPaTNE study proposes to create a retrospective cohort of simultaneous pancreatic and hepatic resections for metastatic neuroendocrine tumors in order to evaluate the short and long term results of this type of resection. The evaluation of the results of this type of resection may be useful for the selection of patients for treatment.

Interventions

None listed

Sponsors

University Hospital, Strasbourg, France
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum

Inclusion criteria

* Major subjects (≥18 years old) * Subject having had a first pancreatic resection for NET with resections of synchronous metastases * Subject having had a first pancreatic resection for NET followed by a delayed resection of synchronous metastases * Subject who has not expressed his opposition, after being informed, to the reuse of his data for the purposes of this research

Exclusion criteria

* Subject who expressed their opposition to participating in the study * Pregnant women * Subject under safeguard of justice * Subjects under guardianship or curatorship

Design outcomes

Primary

MeasureTime frame
Postoperative morbidity and mortality of simultaneous pancreatic and hepatic resectioMorbidity and mortality at 90 postoperative days

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026